Emil D Kakkis insider trades: Ultragenyx Pharmaceutical (RARE) stock buys and sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Emil reports to the SEC
Open-market buys and sales
47 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Mar 2, 2026 | RARE | ↓ Sell | 54,404 | $22.80 | $1.2M | Direct | Mar 3, 2026 (1d) |
| Mar 3, 2025 | RARE | ↓ Sell | 73,434 | $42.10 | $3.1M | Direct | Mar 4, 2025 (1d) |
| Feb 28, 2025 | RARE | ↓ Sell | 25,000 | $42.48 | $1.1M | By Emil Kakkis and Jenny Soriano Living | Mar 4, 2025 (4d) |
| Dec 30, 2024 | RARE | ↓ Sell | 11,727 | $42.23 | $495K | By Emil Kakkis and Jenny Soriano Living | Dec 31, 2024 (1d) |
| Dec 10, 2024 | RARE | ↓ Sell | 8,273 | $50.00 | $414K | By Emil Kakkis and Jenny Soriano Living | Dec 11, 2024 (1d) |
| Sep 3, 2024 | RARE | ↓ Sell | 20,000 | $55.85 | $1.1M | See FN | Sep 5, 2024 (2d) |
| Aug 6, 2024 | RARE | ↓ Sell | 20,000 | $50.17 | $1.0M | See FN | Aug 7, 2024 (1d) |
| Feb 7, 2024 | RARE | ↓ Sell10b5-1 | 30,000 | $45.00 | $1.4M | Direct | Feb 8, 2024 (1d) |
| Dec 29, 2023 | RARE | ↓ Sell10b5-1 | 30,000 | $47.87 | $1.4M | Direct | Jan 2, 2024 (4d) |
| Oct 19, 2023 | RARE | ↓ Sell | 47,853 | $33.52 | $1.6M | Direct | Oct 23, 2023 (4d) |
| Dec 30, 2022 | RARE | ↓ Sell | 19,582 | $45.57 | $892K | Direct | Jan 3, 2023 (4d) |
| May 3, 2021 | RARE | ↓ Sell | 30,000 | $107.80 | $3.2M | By Emil Kakkis and Jenny Soriano Living | May 5, 2021 (2d) |
| Mar 1, 2021 | RARE | ↓ Sell | 30,000 | $141.80 | $4.3M | By Emil Kakkis and Jenny Soriano Living | Mar 3, 2021 (2d) |
| Jan 4, 2021 | RARE | ↓ Sell | 30,000 | $136.90 | $4.1M | By Emil Kakkis and Jenny Soriano Living | Jan 5, 2021 (1d) |
| Nov 2, 2020 | RARE | ↓ Sell | 30,000 | $96.82 | $2.9M | By Emil Kakkis and Jenny Soriano Living | Nov 4, 2020 (2d) |
| Sep 1, 2020 | RARE | ↓ Sell | 30,000 | $82.63 | $2.5M | By Emil Kakkis and Jenny Soriano Living | Sep 2, 2020 (1d) |
| Jul 13, 2020 | RARE | ↓ Sell | 40,000 | $85.35 | $3.4M | By Emil Kakkis and Jenny Soriano Living | Jul 15, 2020 (2d) |
| Sep 11, 2019 | RARE | ↑ Buy | 5,000 | $43.63 | $218K | Direct | Sep 11, 2019 (0d) |
| Aug 28, 2017 | RARE | ↑ Buy | 7,500 | $52.52 | $394K | By Emil Kakkis and Jenny Soriano Living | Aug 29, 2017 (1d) |
| Nov 15, 2016 | RARE | ↓ Sell | 20,000 | $81.29 | $1.6M | Direct | Nov 17, 2016 (2d) |
| Oct 14, 2016 | RARE | ↓ Sell | 20,000 | $63.02 | $1.3M | Direct | Oct 18, 2016 (4d) |
| Aug 15, 2016 | RARE | ↓ Sell | 20,000 | $67.61 | $1.4M | Direct | Aug 17, 2016 (2d) |
| Jul 15, 2016 | RARE | ↓ Sell | 20,000 | $50.85 | $1.0M | Direct | Jul 19, 2016 (4d) |
| May 16, 2016 | RARE | ↓ Sell | 20,000 | $59.95 | $1.2M | Direct | May 18, 2016 (2d) |
| Apr 15, 2016 | RARE | ↓ Sell | 20,000 | $70.33 | $1.4M | Direct | Apr 19, 2016 (4d) |
| Dec 31, 2015 | RARE | ↓ Sell | 20,000 | $114.52 | $2.3M | Direct | Jan 4, 2016 (4d) |
| Nov 30, 2015 | RARE | ↓ Sell | 20,000 | $98.27 | $2.0M | Direct | Dec 2, 2015 (2d) |
| Oct 30, 2015 | RARE | ↓ Sell | 20,000 | $99.57 | $2.0M | Direct | Nov 3, 2015 (4d) |
| Mar 2, 2009 | BMRN | ↓ Sell | 7,897 | $11.70 | $92K | Direct | Mar 4, 2009 (2d) |
| Feb 3, 2009 | BMRN | ↓ Sell | 17,000 | $19.14 | $325K | Direct | Feb 5, 2009 (2d) |
| Jan 2, 2009 | BMRN | ↓ Sell | 17,000 | $17.57 | $299K | Direct | Jan 6, 2009 (4d) |
| Dec 1, 2008 | BMRN | ↓ Sell | 17,000 | $15.87 | $270K | Direct | Dec 2, 2008 (1d) |
| Nov 25, 2008 | BMRN | ↓ Sell | 75,000 | $15.98 | $1.2M | Direct | Nov 25, 2008 (0d) |
| Oct 31, 2008 | BMRN | ↑ Buy | 317 | $13.35 | $4K | Direct | Nov 5, 2008 (5d) |
| Oct 1, 2008 | BMRN | ↓ Sell | 18,000 | $26.27 | $473K | Direct | Oct 3, 2008 (2d) |
| Sep 2, 2008 | BMRN | ↓ Sell | 18,000 | $30.19 | $543K | Direct | Sep 3, 2008 (1d) |
| Aug 1, 2008 | BMRN | ↓ Sell | 18,000 | $32.48 | $585K | Direct | Aug 5, 2008 (4d) |
| Jul 7, 2008 | BMRN | ↓ Sell | 18,000 | $28.06 | $505K | Direct | Jul 18, 2008 (11d) |
| Jun 2, 2008 | BMRN | ↓ Sell | 18,000 | $37.63 | $677K | Direct | Jun 3, 2008 (1d) |
| May 1, 2008 | BMRN | ↓ Sell | 18,000 | $37.49 | $675K | Direct | May 5, 2008 (4d) |
| Apr 30, 2008 | BMRN | ↑ Buy | 1,640 | $10.37 | $17K | Direct | May 5, 2008 (5d) |
| Apr 1, 2008 | BMRN | ↓ Sell | 9,857 | $35.90 | $354K | Direct | Apr 2, 2008 (1d) |
| Apr 1, 2008 | BMRN | ↓ Sell | 8,143 | $35.75 | $291K | Direct | Apr 2, 2008 (1d) |
| Mar 6, 2008 | BMRN | ↓ Sell | 18,000 | $38.16 | $687K | Direct | Mar 10, 2008 (4d) |
| Oct 31, 2007 | BMRN | ↑ Buy | 2,038 | $6.92 | $14K | Direct | Dec 20, 2007 (50d) |
| Apr 30, 2007 | BMRN | ↑ Buy | 2,982 | $5.18 | $15K | Direct | May 2, 2007 (2d) |
| Oct 31, 2006 | BMRN | ↑ Buy | 4,368 | $3.43 | $15K | Direct | Nov 22, 2006 (22d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other RARE insiders
Open-market trades in the last 12 months
About Emil D Kakkis's insider trades
Emil D Kakkis is President & CEO at Ultragenyx Pharmaceutical (RARE). Since Oct 31, 2006, Emil has reported 7 open-market purchases worth $678K and 40 sales worth $55.2M on SEC Form 4. In the last 12 months: 1 sale ($1.2M).
2 sales (5% of the value sold) were made under a Rule 10b5-1 trading plan, which is set up months in advance and runs on a schedule, so they say little about how the insider sees the stock today.
Their filings also include grants and awards (23 filings), shares withheld for taxes (21 filings), option exercises (15 filings), gifts (2 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every RARE insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.